Skip to Content
Merck
CN

SML2401

Sigma-Aldrich

Imeglimin hydrochloride

≥98% (HPLC), powder, anti-hyperglycemic compound

Synonym(s):

(6R)-1,6-dihydro-N,N,6-trimethyl-1,3,5-Triazine-2,4-diamine Hydrochloride,, (6R)-3,6-Dihydro-N2,N2,6-trimethyl-1,3,5-triazine-2,4-diamine, EMD 387008 Hydrochloride, EMD-387008 Hydrochloride, R-(4-Imino-6-methyl-1,4,5,6-tetrahydro-[1,3,5]trazin-2-yl)dimethylamine Hydrochloride

Sign Into View Organizational & Contract Pricing

Select a Size

About This Item

Empirical Formula (Hill Notation):
C6H13N5 · xHCl
CAS Number:
775351-61-6
Molecular Weight:
155.20 (free base basis)
UNSPSC Code:
12352200
NACRES:
NA.77

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Imeglimin hydrochloride, ≥98% (HPLC)

Quality Level

100

Assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

H2O: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

Cl.N1[C@@H](N=C(N=C1N(C)C)N)C

InChI

1S/C6H13N5.ClH/c1-4-8-5(7)10-6(9-4)11(2)3;/h4H,1-3H3,(H3,7,8,9,10);1H/t4-;/m1./s1

InChI key

UXHLCYMTNMEXKZ-PGMHMLKASA-N

Related Categories

Biochem/physiol Actions

Glucose-lowering agent that appears to target mitochondrial bioenergetics
Imeglimin is a first-in-class oral glucose-lowering agent whose mechanism of action targets mitochondrial bioenergetics, resulting in increased insulin secretion in response to glucose, improved glucose uptake by skeletal muscle, and suppression of gluconeogenesis. Imeglimin has been shown to decrease reactive oxygen species overproduction and delay mPTP opening, preventing cell death during oxidative stress, protecting beta-cells. In an animal model, it has been shown to reduce metabolic syndrome-related diabetic cardiomyopathy.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000480322
0000480322
0000416718
0000416721
0000416718

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

P577 Short- and long-term imeglimin treatment reduces metabolic syndrome-related diabetic cardiomyopathy
Lachaux M, Hamzaoui M, Nicol L, Fouqueray P, Bolze S, Hallakou-Bozec S, Richard V, Mulder P
European Heart Journal, 38 (2017)
D Detaille et al.
Cell death discovery, 2, 15072-15072 (2016-08-24)
Imeglimin is the first in a new class of oral glucose-lowering agents, having recently completed its phase 2b trial. As Imeglimin did show a full prevention of β-cell apoptosis, and since angiopathy represents a major complication of diabetes, we studied

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service